Are you seeing the whole picture?
OXILAN® gives you both patient comfort and

**Lowest osmolality of all monomers**
- Low osmolality improves patient comfort and minimizes patient movement
- The threshold of vascular pain was determined to be approximately 700 to 750 mOsms

*In a randomized, parallel, double-blind, controlled study of 112 patients, OXILAN® was well tolerated on patient measures of pain and warmth*

*The clinical significance of this data is not known.*
The whole picture on viscosity

Lowest viscosity of all the monomers at 350-370 concentration

- Low viscosity allows for easy injection through small diameter catheters
- Low viscosity allows for high-speed injection
- Low viscosity provides better flow through small blood vessels and capillaries

Compare the viscosity of OXILAN® 300™

![Graph comparing viscosity of OXILAN® 300™, Omnipaque™, Isovue® 300, Ultravist® 300, Hexabrix®, Visipaque™, and Optiray®.

- 39% less viscosity than Visipaque and 20% less viscosity than Omnipaque at 20°C

Compare the viscosity of OXILAN® 350™

![Graph comparing viscosity of OXILAN® 350™, Omnipaque™, Isovue® 370, Ultravist® 370, Hexabrix®, Visipaque™, and Optiray®.

- 39% less viscosity than Visipaque and 20% less viscosity than Omnipaque at 20°C

the visibility you need
Renal Safety

The OXILAN® balance of low viscosity and low osmolality may help reduce the risk of renal complications*

- Low osmolar contrast media (CM) are as safe as iso-osmolar for contrast-induced nephropathy (CIN), as ICON and CARE studies have shown⁷
- Hydration plays a major role in at least limiting the incidence of CIN⁸
- Osmolality is not a factor in decreasing renal blood flow or glomerular filtration⁹
- High viscosity CM can be responsible for hypoperfusion of the inner medulla and cortex in animal studies¹⁰
- High viscosity can significantly reduce renal blood flow from baseline¹⁰
- Low osmolar dimeric CM may have a greater potential for cytotoxic effects on proximal renal tubular cells than monomeric CM¹¹ (in vitro study)

OXILAN® contains sodium (9 mmol/L Na) with a citrate buffer

- The addition of sodium to CM solutions has been shown to reduce the risk of ventricular fibrillation (VF) in animal studies¹²:
  - OXILAN® produced a much lower incidence of VF compared to other nonionic monomers studied (ioversol¹², iomeprol¹², iopromide¹², iohexol¹³)

Arrhythmia

OXILAN® contains sodium (9 mmol/L Na) with a citrate buffer

- The addition of sodium to CM solutions has been shown to reduce the risk of ventricular fibrillation (VF) in animal studies¹²:
  - OXILAN® produced a much lower incidence of VF compared to other nonionic monomers studied (ioversol¹², iomeprol¹², iopromide¹², iohexol¹³)

Hemodynamics

In these studies vs iohexol, OXILAN®:

- significantly decreased platelet aggregation and activation¹⁴ (clinical study, N=37)
- had less effect on the endothelium¹⁵* (animal study, electron micrograph of aortic rings)
- had minimal effect on mean blood pressure and heart rate¹⁶* (animal study)
- had no negative inotropic effect¹⁶* (animal study)

*The clinical significance of this data is not known. Please see full Prescribing Information for complete disclosure of safety risks and warnings.
The whole picture
on the unique molecular structure

The molecular structure of OXILAN® provides both patient comfort and the visibility you need.

Hydrophilic Group
- Increases solubility which can contribute to rapid renal clearance
- Reduces binding with other molecular structures, which may promote endothelial tolerance

Hydrophobic Region
- Promotes “transient molecular aggregation” of the molecules, reducing osmolality
- Achieves lower osmolality at diagnostically useful concentrations
The whole picture
on the OXILAN® balance

Viscosity is determined by the size of the molecules in solution.
Osmolality is determined by the number of particles in solution.

The low viscosity characteristic of a monomer
balanced with
The low osmolality provided by the hydrophobic region of the molecule

OXILAN® has been used in more than 4.5 million patients since 1996¹

Indications
OXILAN® is available in 2 concentrations for the following indications:

**Intra-arterial**
OXILAN® (ioxilan) Injection (300 mgI/mL) is indicated for cerebral arteriography
OXILAN® (ioxilan) Injection (350 mgI/mL) is indicated for coronary arteriography and left ventriculography, visceral angiography, aortography and peripheral arteriography

**Intravenous**
OXILAN® (ioxilan) Injection (300 mgI/mL) and OXILAN® (ioxilan) Injection (350 mgI/mL) are indicated for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body.
References:

1. Data on file. Guerbet LLC.


OXILAN® (ioxilan) Injection Nonionic Contrast Agent

Product Information

OXILAN® Injection is a non-ionic, triiodinated contrast medium for intravascular injection to enhance radiographic visualization and diagnosis.

All OXILAN® bottles are manufactured latex-free.

NOT FOR INTRATHECAL USE

Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to verify that the drug product is not indicated for intrathecal use. Nonionic iodinated contrast media inhibit blood coagulation, in vitro, less than ionic contrast media. The use of plastic syringes in glass syringes has been reported to decrease but not eliminate the likelihood of in vitro clotting. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary, particularly during angiographic procedures, to minimize thromboembolic events.

Please see accompanying full Prescribing Information

Other brand names are trademarks or registered trademarks of their respective owners.

Oxilan is a registered trademark of Guerbet LLC.

© 2008 Guerbet LLC

When you see the whole picture, OXILAN® looks like the right choice

- Low viscosity for easy administration
- Lowest osmolality of all monomers contributes to patient comfort
- Unique molecular structure contributes to patient comfort and rapid renal clearance
- Contains sodium citrate to reduce the risk of ventilator fibrillation
- Excellent hemodynamic profile

Available in 300 and 350 mg/I/mL latex-free bottles

Single Dose: 50 mL, 100 mL, 150 mL and 200 mL

Pharmacy Bulk Package: 500 mL

For more information, please call 877.729.6679 or visit our Web site at www.guerbet-us.com

References:

1. Data on file. Guerbet LLC.